Clinical Trial: Serum Adropin as an Indicator of Endothelial Dysfunction and Disease Severity in Obstructive Sleep Apnea in Obese Patients

U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07829809) titled 'Serum Adropin as an Indicator of Endothelial Dysfunction and Disease Severity in Obstructive Sleep Apnea in Obese Patients' on Sept. 15.

Brief Summary: 1. Objectives (Aim): To evaluate the role of serum adropin as a potential biomarker of endothelial dysfunction in OSA

1. Compare serum adropin levels between Obese patients with and without OSA.

2. Correlate serum adropin with OSA severity indices including the Apnea-Hypopnea Index (AHI) and Oxygen Desaturation Index (ODI) and cardiovascular complications.

3. Assess the relationship between serum adropin and endothelial dysfunction markers (endothelin-1).

4. Evaluate adropin's p...